Benefits and uses
Rybelsus benefits and uses
Rybelsus is used in adults with type 2 diabetes for two FDA-approved purposes: blood sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events in those at high risk.12 Its label trials report lower HbA1c on 7 mg and 14 mg, and fewer major cardiovascular events on 14 mg than on placebo.1
This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.
Approved uses
- Blood sugar control, approved in 2019: FDA's original approval covered Rybelsus, together with diet and exercise, to improve glycemic control in adults with type 2 diabetes.3
- Cardiovascular risk reduction, approved in 2025: on October 17, 2025, FDA added a use to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes who are at high risk of them.2
Both uses are for adults with type 2 diabetes.1 Anything else people search for sits outside the label, as the evidence table below shows.
What the trials found
Every result here comes from a randomized trial reported on the label, in adults with type 2 diabetes.1 They are group averages, not a forecast for any one person.
Blood sugar
Six label trials enrolled 324 to 1,864 adults each and reported HbA1c at week 26. Across them, HbA1c fell 0.9 to 1.4 points on Rybelsus; in the four with a placebo group, it fell 0.1 to 0.3 points on placebo.1 Rybelsus 14 mg lowered HbA1c more than empagliflozin and sitagliptin tablets, and about as much as daily liraglutide injection.1 Trial-by-trial numbers are in Rybelsus and blood sugar.
Heart and blood vessels
The cardiovascular outcomes trial enrolled 9,650 adults aged 50 or older with type 2 diabetes plus heart or blood vessel disease, chronic kidney disease or both, and followed them for a median of about 49.6 months.1
| Outcome | Rybelsus 14 mg | Placebo | Hazard ratio |
|---|---|---|---|
| First major cardiovascular event1 | 12.0% | 13.8% | 0.86 (95% CI 0.77 to 0.96) |
| Non-fatal heart attack1 | 4.0% | 5.2% | 0.74 |
For cardiovascular death (hazard ratio 0.93) and non-fatal stroke (hazard ratio 0.88), the confidence intervals crossed 1, so neither was clearly lowered on its own.1
A separate cardiovascular safety trial followed 3,183 adults with type 2 diabetes and high cardiovascular risk for a median of 16 months. Major cardiovascular events occurred in 3.8% on 14 mg and 4.8% on placebo (hazard ratio 0.79, 95% CI 0.57 to 1.11), and Rybelsus met the trial's non-inferiority test against placebo.1 Because that interval includes 1, the safety trial alone did not show a reduction; the larger outcomes trial did.1
Weight
Weight fell in the diabetes trials as well, but their primary measure was HbA1c, and weight loss is not an approved use.1 The figures, and the semaglutide tablet that is approved for weight reduction, are on Rybelsus and weight loss.
Evidence at a glance
| Use or outcome | Evidence level | Label status |
|---|---|---|
| Lower HbA1c | Six randomized trials, 324 to 1,864 adults each, HbA1c read at week 261 | Approved use since 20193 |
| Fewer major cardiovascular events | One randomized outcomes trial, 9,650 adults, median about 49.6 months1 | Approved use since 20252 |
| Weight change | Reported in the diabetes trials, whose primary measure was HbA1c1 | Not an approved use1 |
| Prediabetes | Not tested in the label's trials, which enrolled adults with type 2 diabetes1 | Not a labeled use1 |
| Patients under 18 | Safety and effectiveness not established1 | Not a labeled use1 |
Related pages
The Rybelsus profile gives the full overview. Rybelsus side effects lists the trade-offs reported in the same trials, and Rybelsus dosage shows the label schedule behind the 7 mg and 14 mg results. For the drug class as a whole, see GLP-1 benefits and uses; for the weekly injection, see Ozempic benefits and uses.
More on Rybelsus
Rybelsus side effects
Side effects of Rybelsus as reported in labels, trials and published studies, with links to the full profile. Reviewed by a qualified reviewer.
Rybelsus dosage
Published dosing information for Rybelsus from labels and studies, with its source, and why it is not advice for you.
Frequently asked questions
What is Rybelsus used for?
Rybelsus has two FDA-approved uses, both in adults with type 2 diabetes. It is used with diet and exercise to improve blood sugar control, its original use from 2019.3 Since October 2025, it is also used to lower the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in those at high risk.2 It is not approved for weight loss, and the prescriber decides whether it fits a given patient.1
Is Rybelsus effective?
On average, yes, for its approved uses. In six label trials, HbA1c measured at week 26 fell 0.9 to 1.4 points on Rybelsus, against 0.1 to 0.3 points in the four trials that had a placebo group.1 In the outcomes trial that followed 9,650 high-risk adults for a median of about 49.6 months, major cardiovascular events occurred in 12.0% on 14 mg and 13.8% on placebo.1 These are group results from adults with type 2 diabetes, not a prediction for any one person.
Does Rybelsus lower the risk of heart attack?
In the label's cardiovascular outcomes trial of 9,650 high-risk adults with type 2 diabetes, non-fatal heart attacks occurred in 4.0% on Rybelsus 14 mg vs 5.2% on placebo (hazard ratio 0.74).1 FDA's October 2025 approval covers cardiovascular death, non-fatal heart attack and non-fatal stroke as one combined risk.2 For cardiovascular death and non-fatal stroke on their own, the trial's confidence intervals crossed 1.1
Does Rybelsus help people with kidney disease?
In a 26-week trial of 324 adults with moderate kidney impairment (eGFR 30 to 59, mean age 70), HbA1c fell 1.0 point on 14 mg vs 0.2 on placebo.1 That is a blood sugar result in people with weaker kidneys, not a kidney-protection result. Lowering the risk of kidney decline is a use on the Ozempic injection label, not on the Rybelsus label.41 The Rybelsus dose is the same with or without kidney problems.1
Written by D2C Peptides Editorial Team.
Pending qualified review.
Updated .
Sources
- RYBELSUS and OZEMPIC (semaglutide) tablets, Prescribing Information and Medication Guide (NDA 213051/S-030, revised 1/2026). U.S. Food and Drug Administration (Novo Nordisk labeling), 2026.
- Supplement approval letter, NDA 213051/S-024, S-028, S-029 (cardiovascular risk reduction indication). U.S. Food and Drug Administration, 2025.
- Approval letter, NDA 213051 Rybelsus (semaglutide) tablets. U.S. Food and Drug Administration, 2019.
- OZEMPIC (semaglutide) injection prescribing information, Indications and Usage; DailyMed listing. DailyMed, U.S. National Library of Medicine (Novo Nordisk label, revised 5/2026), 2026.